Last updated: May 2, 2026
VIZIMPRO (dacomitinib): Clinical Trials Update, Market Analysis, and Projections
What is VIZIMPRO and where does it fit clinically?
VIZIMPRO is dacomitinib (PF-00299804), an oral, irreversible epidermal growth factor receptor (EGFR) inhibitor. The drug’s marketed positioning is EGFR-mutant non-small cell lung cancer (NSCLC), with the dominant use case being first-line treatment in patients with metastatic NSCLC whose tumors have activating EGFR mutations.
Regulatory anchors (US):
- Accelerated approval: 2018 for patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that progressed on EGFR TKI therapy.
- Full approval (first-line): based on ARCHER 1050 results for metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.
Key clinical decision points (practice):
- First-line adoption vs. chemotherapy in EGFR exon 19 del or L858R is driven by overall survival (OS) and progression-free survival (PFS) versus comparator TKIs in ARCHER 1050.
- Real-world utilization typically increases when payer coverage and first-line sequencing guidelines align with dacomitinib’s label and evidence package.
Source anchor for indications and trial context: FDA label and pivotal trial publications for ARCHER 1050 and the first-line EGFR exon 19 del/L858R population. [1–3]
What is the current clinical trials update for dacomitinib?
Clinical development for dacomitinib is dominated by (1) label expansion within EGFR-mutant NSCLC, and (2) sequencing and combination studies across resistance settings (post-progression and peri-progression).
Trial landscape by program theme (high level):
1) First-line EGFR-mutant metastatic NSCLC
- The first-line evidence base remains anchored by ARCHER 1050 (dacomitinib vs gefitinib).
- Current activity is often consolidation-oriented: subgroup analyses, biomarker-stratified follow-up, and competitive sequencing studies rather than a wholesale replacement of the core label.
Pivotal efficacy evidence (ARCHER 1050):
- Reported efficacy signals include improvements in PFS and OS compared with gefitinib in the EGFR exon 19 del/L858R population, forming the label justification. [1–3]
2) Resistance and subsequent-line strategies
- Development activity centers on overcoming acquired resistance pathways and optimizing post-progression sequencing.
- These studies frequently include combination arms with chemotherapy, anti-angiogenics, or immunotherapy backbones, while maintaining EGFR inhibition.
3) Combination studies
- Dacomitinib combinations target biologically plausible resistance mechanisms and aim to extend disease control beyond EGFR-TKI monotherapy.
- In practice, these studies compete for later-line and investigational positioning given the strength of first-line standards of care.
Where the market “feels” these trials:
Even when trials target later settings, success can shift payer and guideline behavior by:
- strengthening competitive sequencing,
- expanding eligible subgroups (mutational or resistance-defined),
- improving access through narrower biomarker definitions.
Source base for ongoing development visibility: Clinical trial records for dacomitinib include ARCHER 1050 publication context and ongoing interventional studies under the dacomitinib umbrella on ClinicalTrials.gov. [4]
What endpoints and evidence are driving adoption (not just publicity)?
Adoption is driven by endpoints that translate into regimen selection.
Primary endpoints typically used for label-relevant decision making:
- Overall survival (OS): determines whether payers and guidelines treat the regimen as a survival-dominant standard.
- Progression-free survival (PFS) and objective response rate (ORR): drive earlier adoption in settings where OS data mature more slowly.
- Safety and tolerability profile: affects real-world persistence and dose optimization, especially with irreversible EGFR inhibition.
Pivotal trial relevance:
- ARCHER 1050 is the clinical evidence foundation for first-line dacomitinib positioning in the EGFR exon 19 del/L858R metastatic NSCLC population. [1–3]
How is VIZIMPRO positioned in the EGFR NSCLC competitive landscape?
The EGFR-mutant metastatic NSCLC space is shaped by:
- first-generation EGFR TKIs (e.g., erlotinib, gefitinib),
- second-generation irreversible TKIs (dacomitinib),
- third-generation EGFR TKIs (e.g., osimertinib),
- combination approaches and chemo-immunotherapy standards for broader molecular populations.
Competitive differentiators that matter commercially:
- Line of therapy (first-line positioning is the most commercially meaningful).
- Mutation specificity (exon 19 del / L858R focus for core label).
- Survival versus comparator strength (OS and durability).
- Tolerability and dose intensity (affects continuation and administrative burden).
Net effect: First-line EGFR-mutant metastatic NSCLC is where dacomitinib’s evidence most directly translates into prescriptions, if guideline and payer coverage align.
Evidence source for comparative framing: FDA label and ARCHER 1050 publication details are the commercial basis for positioning. [1–3]
Market Analysis: revenue drivers, uptake patterns, and pressure points
What is the market size for EGFR-mutant metastatic NSCLC where VIZIMPRO competes?
The relevant market is defined by:
- molecularly selected metastatic NSCLC,
- EGFR activating mutations (exon 19 del, L858R as core),
- first-line and sequencing lines that allocate prescriptions to EGFR TKIs rather than chemo-only regimens.
Market sizing mechanics (directional framework):
- Incidence of metastatic NSCLC in treated populations.
- Share tested for EGFR mutations.
- Fraction with activating EGFR mutations.
- Fraction with exon 19 del and L858R (label-relevant subset).
- Split by lines of therapy where EGFR-TKIs are used first-line.
Why this matters for projection: VIZIMPRO’s addressable share depends on (a) biomarker testing saturation and (b) whether competing EGFR TKIs win first-line selection based on OS, tolerability, and payer coverage.
Data sources for clinical and regulatory anchor: FDA and trial records establish the label-relevant population definition and study comparisons. [1–3]
What are the key commercial revenue drivers for dacomitinib?
Revenue drivers:
- First-line conversion rate among EGFR exon 19 del/L858R metastatic NSCLC patients.
- Time-on-treatment driven by tolerability and management of class adverse events (rash, diarrhea).
- Formulary placement and coverage breadth by payer.
- Sequencing dynamics: whether clinicians treat dacomitinib as default first-line or reserve it for certain profiles.
Revenue risks:
- Competitive substitution in first-line by other EGFR TKIs with strong survival data.
- Access constraints through step therapy or prior authorization.
- Safety-driven discontinuation if real-world dose intensity drops due to adverse events.
Evidence anchor: Dacomitinib’s label and trial evidence define the core patient selection. [1–3]
What market pressures are likely to shape performance over the next 3 to 5 years?
1) Competitive dynamics in first-line EGFR-mutant NSCLC
- Competitors with strong OS datasets and broad payer access can cap share growth.
- Dosing and adverse event management drive relative persistence.
2) Guideline and payer behavior
- Where guidelines present dacomitinib as an option based on OS/PFS strength, uptake rises.
- Payer restrictions reduce share even with clinical evidence.
3) Biomarker and testing penetration
- Growth in molecular testing supports addressable market expansion.
- However, growth is shared across all EGFR-targeted drugs.
4) Resistance and progression patterns
- If resistance landscapes shift (e.g., more frequent EGFR C797S or compound mutations), sequencing strategy changes and can reduce relative use if alternative TKIs or combinations dominate post-progression.
Trial and label anchor: Ongoing clinical development and labeling define competitive constraints and expansion opportunities. [1–4]
Projections: uptake, revenue trajectory, and scenario logic
How should projections be constructed for VIZIMPRO?
A practical projection model for dacomitinib relies on:
- Eligible patient pool (EGFR exon 19 del/L858R metastatic NSCLC treated population),
- First-line share among EGFR exon 19 del/L858R,
- Payer adoption rate (formulary and utilization),
- Persistence curve (time on therapy),
- Price dynamics (list price trends and net-to-gross outcomes).
Commercial math (structure, not proprietary inputs):
| Projection block |
Primary lever |
What it changes |
| Addressable population |
EGFR testing penetration and eligible mutation prevalence |
Total potential prescriptions |
| Share of EGFR first-line |
Relative guideline/payer adoption vs other EGFR TKIs |
Market share |
| Treatment duration |
Discontinuation and dose intensity in real world |
Units per patient |
| Net price |
Contracting, rebates, payer mix |
Revenue per unit |
Evidence tie-in: ARCHER 1050 informs the survival justification that influences share. [1–3]
What is the likely direction of market trajectory?
Base-case direction: steady growth or plateau with modest share gains in pockets where:
- dacomitinib is preferred by guidelines for specific EGFR profiles,
- payers maintain broad access,
- real-world tolerability supports longer treatment duration.
Downside case: plateau or decline if:
- competitors expand first-line preference through superior perceived tolerability,
- payer controls tighten through step edits,
- competitive evidence in adjacent subgroups reshuffles sequencing.
Upside case: share gains if:
- biomarker-defined subgroup support expands,
- combination strategies improve outcomes and strengthen first-line positioning,
- real-world management protocols increase persistence.
Clinical evidence driver: the durability of dacomitinib’s benefit in the label-defining EGFR exon 19 del/L858R population. [1–3]
Key Takeaways
- VIZIMPRO (dacomitinib) is an EGFR-mutant metastatic NSCLC therapy with commercial weight concentrated in the first-line EGFR exon 19 del/L858R segment, supported by the ARCHER 1050 survival and efficacy evidence package and reflected in label positioning. [1–3]
- Clinical development focus remains on label consolidation, sequence optimization, and combination strategies designed to improve control beyond EGFR-TKI monotherapy. [4]
- Market performance over the next 3 to 5 years is most sensitive to (1) first-line share capture, (2) persistence driven by tolerability, and (3) payer/formulary coverage more than to marginal incremental trial announcements. [1–3]
- Projections should be built around eligible patient pool, first-line share, persistence, and net price; the evidence base defines the share and access ceiling. [1–3]
FAQs
-
What is VIZIMPRO’s main commercial indication?
First-line treatment of metastatic NSCLC with activating EGFR exon 19 deletions or exon 21 L858R mutations, plus other EGFR-mutant settings reflected in the US label based on clinical evidence. [1]
-
Which trial anchors the first-line positioning?
ARCHER 1050, comparing dacomitinib with gefitinib in the EGFR exon 19 del/L858R metastatic NSCLC population. [2,3]
-
What determines whether VIZIMPRO gains or loses first-line share?
Guideline inclusion, payer formulary placement, and real-world persistence based on tolerability management, anchored to OS/PFS evidence strength. [1–3]
-
Does dacomitinib’s development focus on combinations or sequencing?
The dacomitinib pipeline includes studies oriented to sequencing and combinations within EGFR-mutant NSCLC, visible through ClinicalTrials.gov interventional records. [4]
-
How should unit demand be projected for VIZIMPRO?
By combining eligible patient volume with first-line share and a persistence curve derived from real-world discontinuation and dose intensity behavior, using trial evidence for clinical adoption logic. [1–3]
References
[1] U.S. Food and Drug Administration. VIZIMPRO (dacomitinib) prescribing information. FDA label.
[2] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib and Dacomitinib in EGFR-mutated NSCLC (clinical evidence context including ARCHER 1050). Journal publication details as reflected in FDA and labeled evidence.
[3] U.S. FDA. Approval history and label basis for VIZIMPRO including ARCHER 1050 efficacy rationale.
[4] ClinicalTrials.gov. Dacomitinib (PF-00299804) clinical trials records (ongoing and completed interventional studies).
